Schrödinger, Inc.

NASDAQ:SDGR

Medical - Healthcare Information Services

Healthcare
$27.20 +0.01%

+$0.00 today

Market cap
$1.79B
Beta
1.64
P/E (TTM)
-11.1
EPS (TTM)
-$1.40
52W Low $10.95High $23.75

Volume 1.18M

Average 1.35M

SDGR Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Schrödinger, Inc.NASDAQ: SDGR

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin widens to 59.3%

Gross margin was 59.3% in Q3 FY2026, up 7.7 pp from a year earlier. On a trailing-twelve-month basis it was 58.5%, up 0.4 pp year over year. Over 3 fiscal years it narrowed by 0.1 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
59.3%+4.2 pp QoQ
Last fiscal yearDec 2025
55.7%-7.9 pp YoY
LTMSep 2026
58.5%+0.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+7.7 pp——
1 year-7.9 pp——
3 years-0.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
55.7%
Year-over-year change
-7.9pp

Gross Margin vs competitors

How SDGR compares with its peers on the latest reported figures

  • SDGR's LTM Sep 2026 gross margin of 58.5% is the 5th highest of the 8 companies compared; the peer median is 60.3%.
  • Its year-over-year change of +0.4 pp is the 4th highest of 8, against a peer median of +0.0 pp.
  • Over three fiscal years its change of -0.1 pp compares with a peer median of -0.2 pp.
SDGR Competitors Peer median
Gross Margin for SDGR and competitors
Company Period LTM level YoY 3-year change
GENBGenerate Biomedicines, Inc.FY2025100.0% +0.0 pp—
VEEVVeeva Systems Inc.LTM Jul 202674.9% -0.7 pp+3.8 pp
SLPSimulations Plus, Inc.LTM Feb 202662.0% +6.7 pp-21.5 pp
HYFTMindWalk Holdings Corp.LTM Jan 202660.3% +10.9 pp-1.5 pp
SDGRSchrödinger, Inc.LTM Sep 202658.5% +0.4 pp-0.1 pp
CERTCertara, Inc.LTM Mar 202658.1% -2.1 pp+1.0 pp
ABCLAbCellera Biologics Inc.LTM Sep 2026-18.7% -118.7 pp-24.7 pp
RLAYRelay Therapeutics, Inc.LTM Jun 2026-566.6% +1757.0 pp+17573.1 pp
LTRNLantern Pharma Inc.FY2025— ——
Peer median (excluding SDGR) 60.3%+0.0 pp-0.2 pp

Competitors are the stored peer set for SDGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue137.93M180.96M216.67M207.54M255.87M
Cost of Revenue72.31M79.93M75.97M75.46M113.26M
Gross Profit65.62M101.02M140.69M132.08M142.61M
Gross Margin47.6%55.8%64.9%63.6%55.7%
Research & Development90.9M126.37M181.77M201.79M173.14M
Selling, General & Admin86.16M121.47M136.37M139.59M136.37M
Operating Expenses177.06M247.84M318.14M341.38M309.51M
Depreciation & Amortization2.85M4.34M5.55M6.16M6.02M
EBITDA(97.96M)(144.78M)48.47M(179.55M)(96.3M)
EBITDA Margin-71.0%-80.0%22.4%-86.5%-37.6%
Operating Income(111.44M)(146.82M)(177.45M)(209.3M)(166.9M)
Operating Margin-80.8%-81.1%-81.9%-100.8%-65.2%
Interest Income1.06M3.95M000
Interest Expense03K000
Other Income / Expenses10.64M(2.31M)220.37M23.59M64.57M
Income Before Tax(100.81M)(149.12M)42.92M(185.71M)(102.33M)
Pre-Tax Margin-73.1%-82.4%19.8%-89.5%-40.0%
Income Tax Expense411K63K2.2M1.41M939K
Net Income(100.39M)(149.19M)40.72M(187.12M)(103.27M)
Net Margin-72.8%-82.4%18.8%-90.2%-40.4%
EPS (Basic)(1.43)(2.10)0.57(2.57)(1.41)
EPS (Diluted)(1.43)(2.10)0.54(2.57)(1.41)
Weighted Avg Shares70.59M71.17M71.78M72.67M73.44M
Weighted Avg Shares (Diluted)70.59M71.17M74.99M72.67M73.44M

Schrödinger, Inc.

NASDAQ:SDGR

Intrinsic Alpha fair value

Locked

Current Price

$27.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.